158 related articles for article (PubMed ID: 36673982)
1. Identification of a Novel Gene Signature with DDR and EMT Difunctionalities for Predicting Prognosis, Immune Activity, and Drug Response in Breast Cancer.
Zhang P; Li Q; Zhang Y; Wang Q; Yan J; Shen A; Hu B
Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36673982
[TBL] [Abstract][Full Text] [Related]
2. Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer.
Li C; Zheng L; Xu G; Yuan Q; Di Z; Yang Y; Dong X; Hou J; Wu G
Front Endocrinol (Lausanne); 2023; 14():1154741. PubMed ID: 37538794
[TBL] [Abstract][Full Text] [Related]
3. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
Li Q; Xiao X; Feng J; Yan R; Xi J
Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of biomarkers for epithelial-mesenchymal transition-related cells to estimate the prognosis and immune microenvironment in primary gastric cancer by the integrated analysis of single-cell and bulk RNA sequencing data.
Shen K; Ke S; Chen B; Zhang T; Wang H; Lv J; Gao W
Math Biosci Eng; 2023 Jun; 20(8):13798-13823. PubMed ID: 37679111
[TBL] [Abstract][Full Text] [Related]
5. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.
Wang D; Wei G; Ma J; Cheng S; Jia L; Song X; Zhang M; Ju M; Wang L; Zhao L; Xin S
BMC Cancer; 2021 May; 21(1):645. PubMed ID: 34059009
[TBL] [Abstract][Full Text] [Related]
6. An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer.
Zhang B; Zhao R; Wang Q; Zhang YJ; Yang L; Yuan ZJ; Yang J; Wang QJ; Yao L
Adv Ther; 2023 Oct; 40(10):4339-4357. PubMed ID: 37462865
[TBL] [Abstract][Full Text] [Related]
7. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
Front Immunol; 2021; 12():805883. PubMed ID: 35095892
[TBL] [Abstract][Full Text] [Related]
8. An
Han Y; Wong FC; Wang D; Kahlert C
Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
[TBL] [Abstract][Full Text] [Related]
9. Identification and verification of eight cancer-associated fibroblasts related genes as a prognostic signature for head and neck squamous cell carcinoma.
Dong L; Sun Q; Song F; Song X; Lu C; Li Y; Song X
Heliyon; 2023 Mar; 9(3):e14003. PubMed ID: 36938461
[TBL] [Abstract][Full Text] [Related]
10. A Novel Inflammatory Response-Related Gene Signature Predicts Immune Status and Prognosis of Breast Cancer.
Zhao R; Xie C; Gong Y; Wei S; Yuan M; Gan J; Chen W
J Oncol; 2022; 2022():5468858. PubMed ID: 36467500
[TBL] [Abstract][Full Text] [Related]
11. The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer.
Zhao Z; Mak TK; Shi Y; Huang H; Huo M; Zhang C
Front Immunol; 2023; 14():1117255. PubMed ID: 37457685
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
13. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
14. Systematic construction and validation of an epithelial-mesenchymal transition risk model to predict prognosis of lung adenocarcinoma.
Tang Y; Jiang Y; Qing C; Wang J; Zeng Z
Aging (Albany NY); 2020 Dec; 13(1):794-812. PubMed ID: 33340396
[TBL] [Abstract][Full Text] [Related]
15. Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer.
Shu W; Wang Z; Zhang W; Zhang J; Zhao R; Yu Z; Dong K; Wang H
Comb Chem High Throughput Screen; 2023; 26(8):1488-1502. PubMed ID: 36200154
[TBL] [Abstract][Full Text] [Related]
16. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
[No Abstract] [Full Text] [Related]
17. A novel epithelial-mesenchymal transition (EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma.
Cui Y; Wang X; Zhang L; Liu W; Ning J; Gu R; Cui Y; Cai L; Xing Y
Front Oncol; 2022; 12():974614. PubMed ID: 36185284
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Novel Gene Signature for Predicting the Prognosis of Idiopathic Pulmonary Fibrosis Based on Three Epithelial-Mesenchymal Transition and Immune-Related Genes.
Zheng J; Dong H; Zhang T; Ning J; Xu Y; Cai C
Front Genet; 2022; 13():865052. PubMed ID: 35559024
[No Abstract] [Full Text] [Related]
19. Identification of a novel prognostic signature correlated with epithelial-mesenchymal transition, N6-methyladenosine modification, and immune infiltration in colorectal cancer.
Qu X; Tan H; Mao J; Yang M; Xu J; Yan X; Wu W
Cancer Med; 2023 Mar; 12(5):5926-5938. PubMed ID: 36281556
[TBL] [Abstract][Full Text] [Related]
20. DNA damage repair molecular subtype derived immune signature applicable for the prognosis and immunotherapy response prediction in colon cancer.
Shang Z; Wang Z; Zhang Y; Liu S
Transl Cancer Res; 2023 Oct; 12(10):2781-2805. PubMed ID: 37969400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
